The show Pharmacor 2010 findings from the topic entitled Prostate Cancer that sales of new therapies, especially the Dendreon Provenge , will make around 57 % of the total prostate cancer market in 2019 read more more info . In addition to Provenge, market growth is zibotentan by taking Sanofi-Aventis’ Jevtana, AstraZeneca, Johnson & Johnson’s abiraterone, Amgen / GlaxoSmithKline / Daiichi Sankyo Prolia, Medivation / Astellas Pharma MDV-3100, Algeta / Bayer Schering Pharma Alpharadin be run, Bristol-Myers Squibb’s Sprycel and Celgene Revlimid. By 2019. Have Among the emerging therapies, Provenge won regulatory approval in the United States earlier this year in asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer, the most important impact on the market, said Decision Resources Analyst Andrew Merron, Provenge is the only emerging therapy, we expect to reach blockbuster status by 2019. However, several other representatives to earn a turnover of over $ 500 million because the market is closely and highly competitive over the next decade. .
All company, brand or product names contained may be trademarks may be trademarks or registered trademarks of their respective owners.
go to this link
The technology requires a reliable said luminescent the luminescent terbium sensor through a living Dirt or damage contamination or damage of the cell. The researchers led a way of to co-opt pinocytosis, the process of in small quantities in small quantities by the cell of the surrounding liquid. – ‘This new tool, we hope to cell biologists and others will to be able what they not considered how interactions not visualized in live cells may be studied in real time, ‘Miller said. ‘Hopefully the process supply information that be is lighter derived about biologic mechanisms. ‘.